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Health professionals tasked with advising patients with asthma and chronic obstructive pulmonary disease (COPD) how to use
inhaler devices properly and what to do about unwanted effects will be aware of a variety of commonly held precepts. The
evidence for many of these is, however, lacking or old and therefore in need of re-examination. Few would disagree that facilitating
and encouraging regular and proper use of inhaler devices for the treatment of asthma and COPD is critical for successful
outcomes. It seems logical that the abandonment of unnecessary or ill-founded practices forms an integral part of this process: the
use of inhalers is bewildering enough, particularly with regular introduction of new drugs, devices and ancillary equipment, without
unnecessary and pointless adages. We review the evidence, or lack thereof, underlying ten items of inhaler ‘lore’ commonly passed
on by health professionals to each other and thence to patients. The exercise is intended as a pragmatic, evidence-informed review
by a group of clinicians with appropriate experience. It is not intended to be an exhaustive review of the literature; rather, we aim to
stimulate debate, and to encourage researchers to challenge some of these ideas and to provide new, updated evidence on which
to base relevant, meaningful advice in the future. The discussion on each item is followed by a formal, expert opinion by members
of the ADMIT Working Group.
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INTRODUCTION
‘It ain't what you don't know that gets you into trouble.
It's what you know for sure that just ain't so’.
Mark Twain
Inhaled medication is essential for the treatment of patients with
asthma and chronic obstructive pulmonary disease (COPD), and
incorrect use has well-demonstrated detrimental implications for
patients.1 The effects of these medications depend, among other
factors, upon the amount of the drug deposited in the lower
airways. This is determined by the patient’s inhalation technique,
which is influenced by characteristics of the individual inhaler
devices and the medication therein.
There are two principal types of inhalation device: pressurised
metred dose inhalers (pMDIs) and dry powder inhalers (DPI).
Although advice about how to use these devices properly
originates from many sources, it is typically provided by the
patient’s health professionals, including pharmacists. This insular
arrangement may result in propagation of local habits and beliefs,
which may not be evidence based.
The purpose of this pragmatic, evidence-informed review is to
consider the evidence, or lack thereof, underlying ten common
‘inhaler lore’ beliefs, selected on the basis of the combined clinical
experience and research expertise of the authors.
The authors sourced evidence from their own bibliographical
databases supplemented by a targeted Pubmed search using the
following terminology: (Inhaler or DPI or ‘Dry Powder Inhaler’ or
pMDI or ‘pressurised metred dose inhaler’) AND (‘inhalation
therapy’ or ‘different inhalers’ or ‘mixed inhalers’ or ‘simultaneous
use’ or ‘concomitant use’ or prime or priming or exhale or
exhalation or hold or ‘breath hold’ or shake or shaken or rinse
or rinsing or ‘mouth rinse’ or ‘mouth rinsing’ or spacer or empty or
emptied or caries or ‘dental caries’ or dysphonia or hoarseness or
thrush or candida or candidiasis or outcome or ‘clinical outcome’
or prefer or preference or oropharyngeal candidiasis or dysphonia
or switch or single or multiple or tidal).
The 10 issues listed are not intended to be hierarchical or
all-inclusive but do, in our view, cover the major issues related to
current inhaler prescribing. Concluding statements follow the
discussion on each topic and represent the consensus view of
the panel.
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BELIEFS, SUPPORTING DATA AND PANEL CONCLUSIONS
1. pMDI inhaler devices should be shaken
When chlorofluorocarbon (CFC) propellants were used in pMDIs,
the active drug was typically included as a micronised suspension
and not as a solution. As a result, failure to shake the device either
before use or between successive dosages resulted in improper
dispersion or ‘settling’ of the suspension in the propellant, which
was clearly shown in studies to reduce the delivery of both
β2-agonists and corticosteroids by up to 50%.
2,3 Consequently,
with the old CFC-driven pMDI devices, shaking the device before
each and every dosage was critically important.
Modern pMDIs now universally contain hydrofluoroalkane (HFA)
instead of CFC.4 In many, but in not all, of these devices, the active
drugs are in true solution5 and thus shaking is unnecessary. It is the
responsibility of the prescribing physician and dispensing pharma-
cists to determine whether or not any particular device contains
drug in micronised form or in true solution when advising patients
on the importance of shaking inhalers before use.
Pending clarification from the aerosol scientists and device
manufacturers, we recommend shaking in the interim. While failure
to shake some devices may reduce drug delivery, so far there have
been no studies demonstrating any clinical consequences.
Conclusions
(1) The use of HFA-propelled drugs in true solution in pMDIs
removes the necessity to shake the device.
(2) Because not all pMDI devices contain drugs in true solution
but in micronised form, advising shaking of the device before
each and every dosage is the best default position where
doubt exists.
(3) DPI devices should not be shaken or inverted after priming,
and prescribers should make patients aware of this.
(4) Future studies are needed to clarify the clinical consequences,
if any, of failure to shake relevant pMDI devices before each
dosage and of DPI shaking before or after priming.
2. Spacer design and construction make a difference
Aside from removing the problem of co-ordinating activation of
pMDIs with inhalation, the use of a spacer augments the time
between expulsion of the aerosolised particles from the device
and their inhalation. This serves two particular functions. First,
it facilitates evaporation of the particles to a size capable of
penetrating through the entire bronchial tree as far as the alveoli
(i.e., with mass median diameter less than ~ 5 microns: particles
emitted directly from a pMDI device are initially much larger).
Second, it facilitates slow inhalation of the evaporated particles
into the lungs, which is essential if they are to negotiate beyond
the right-angle bend between horizontal emission from the spacer
device and the vertical passage through the larynx. It has been
shown that several varieties of commercially available spacer
devices increase the proportion of particles emitted from a typical
HFA-propelled pMDI device.6
Most spacer devices are constructed of plastic, which may
accumulate electrostatic charge, which in turn attracts the aerosol
particles, making them unavailable for inhalation. Several studies
demonstrating this effect show that it is reduced by ‘priming’
of the device either by regular use or by spraying extra doses of the
medication into the spacer before use (although this is wasteful).7–10
Regular detergent washing and drip-drying or air-drying (rather than
wiping or rubbing, which adds to surface charge) of spacers is also
helpful.7,10 Some spacers are constructed of non-electrostatic
material. For example, the Nebuchamber (also known as the NES-
spacer) is made of lightweight metal, which was shown not to
require priming,10,11 and it has been suggested to improve total
deposition of budesonide compared with plastic spacer devices.9
Similarly, the Aerochamber Max is a small-volume device con-
structed from a charge-dissipative polymer, which has been shown
to emit a significantly greater proportion of fine mass particles (drug
particles o5 microns in diameter), with either a 2- or 5 -s delay,
compared with spacers made from non-conducting materials, even
with pre-washing.12
It is important for patients to understand that, when using a
spacer, inhalation should commence promptly:13 that is, within 3 s
of actuating the pMDI. This is because aerosolised drug particles
remain suspended in the the spacer for less than 10 s.14
Despite these observations, few, if any, studies have
demonstrated clear benefits of spacer handling or design in
clinical practice. One study of 64 young children found no
difference in the bronchodilatation caused by salbutamol
delivered by an HFA-propelled pMDI through a brand new
Babyhaler, a detergent-coated, reduced static Babyhaler or a metal
NES-spacer.15 In another study on young children treated with
fluticasone propionate administered with an HFA-propelled pMDI,
anti-static treatment of the valve-holding chamber and mask,
which was being used to deliver the drug, resulted in
increased lung bioavailability, but the possible beneficial clinical
consequences of this were not examined.16
Taking multiple tidal breaths from a large-volume spacer may
be more practical than taking single deep breaths, especially for
children, and this appears to be effective at least in terms of
bronchodilation.17 The number of breaths required to empty the
spacer obviously depends on the size of both the device and the
patient. Bisgaard18 recommends 10 breaths in infants, 5 breaths in
toddlers and 2 deep inhalations in older children and adults.
Although it is clear therefore that individual spacer devices may
vary in their emission of fine mass particles and their propensity to
accumulate static charge, there is a paucity of clinical evidence on
which to base recommendations about using one device over
another.
Conclusions
(1) Spacer devices should not be considered interchangeable, as:
a. Metal spacers do not need priming.
b. Plastic spacers may become more efficient after priming, but
the clinical implications of this are unclear and the
procedure is wasteful of medication.
(2) Detergent-washing and drip-drying/air-drying (rather than
wiping or rubbing, which adds to the surface charge) of
spacers is recommended on a regular basis, although to our
knowledge this has not been demonstrated to improve
asthma control. Nevertheless, it seems sensible to adhere to
manufacturers’ advice regarding washing and routine replace-
ment of spacer devices, and clearly they should be replaced if
irretrievably soiled or damaged.
(3) Studies are required to investigate the possible clinical
consequences, if any, of using different spacer devices with
or without measures to reduce static charge.
3. Breath-holding after inhalation is clinically beneficial
Inhaled particles exert their therapeutic effects after making
contact with the surface of the bronchial or alveolar epithelium
and delivering the drugs they contain to their receptors on cells
situated therein. As this contact is initiated by random collision of
the particles with the epithelial surface during Brownian motion,19
it would appear intuitive to hypothesise that exhalation soon after
inhalation, particularly with fine particles before they interact with
the epithelium, could reduce clinical efficacy of the drug. It is very
difficult to address this hypothesis because many other aspects of
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inhaler technique, such as the speed and extent of inhalation, can
also influence particle deposition. Furthermore, it is also very
difficult to detect small changes in clinical effects in the short term
that may result from breath-holding.
One study20 using radiolabelled Teflon particles with a mass
median aerodynamic diameter of 3.2 microns found that a 10- s
compared with a 4-s breath-hold significantly increased lung
deposition of the particles, but only if (i) inspiration was initiated
at 50–80% of vital capacity, which is not how inhalers are
generally taken, and (ii) inspiration was slow (25 l m− 1, as is
generally recommended routinely). There was no measurable
effect when inhalation was initiated at 20% of vital capacity
(the more usual situation when using an inhaler routinely) or
when the inspiratory flow rate was high (approximately 80 litres
per minute).20 Similar findings were reported in another study.21
A pharmacokinetic study using carefully standardised inhalation
manoeuvres showed significantly greater bioavailability of
salbutamol absorbed from the airways following a 10-s breath-
hold compared with no breath-hold.22
Other studies have addressed this hypothesis by using the
clinical bronchodilator response to an inhaled β2-agonist as
an end point.23–28 None of these demonstrated any significant
difference in the bronchodilatation induced by a 10-s as
compared with a 4-s breath-hold or no breath-hold.
A recent review noted variation in advice provided about
breath-holding in a group of patient-orientated checklists
produced by the manufacturers of various inhalation devices: in
particular, one DPI manufacturer made no reference to the
necessity for breath-holding at all. In view of this, the authors
suggested a pragmatic approach by advising patients to hold their
breath for at least 5 s.29
In summary, the conclusion that breath-holding significantly
influences the clinical effects of inhaled bronchodilators must
remain tentative. A caveat is that all of the studies cited above
were performed with now obsolete, relatively large particle CFC
propellant-driven pMDIs. To our knowledge, there are no studies
of the effects of breath-holding time on wanted or unwanted
effects of DPIs, spacer devices or fine-particle pMDIs delivering
bronchodilators or inhaled corticosteroids. At least in theory,
the effect of breath-holding time may be more critical with
fine-particle pMDIs, as one might hypothesise that these are likely
to require a more protracted period to settle in the airways
through Brownian motion, but so far as we are aware there are no
relevant studies.
Conclusions
(1) Breath-holding after inhalation from a pMDI may increase
deposition of the inhaled drug in the airways, but no studies,
to our knowledge, have demonstrated improved bronchodi-
latation or any long-term therapeutic consequences as a
result.
(2) As it is possible that breath-holding may be beneficial when
using inhaler devices with an otherwise perfect technique, a
pragmatic approach, until further evidence becomes available,
is to advise all patients to breath-hold for at least 5 s.
(3) Future studies should investigate the clinical importance of
breath-holding when using dry powder inhalers, spacer
devices and fine-particle pMDIs.
4. Rinsing of the mouth after using an inhaler is clinically beneficial
Patients are often advised to ‘rinse and spit’ or gargle after using
an inhaler device, particularly one containing corticosteroid.
Intuitively, this might be expected to decrease local
oropharyngeal adverse effects of inhaled corticosteroids,
especially oral candidiasis (thrush), although not dysphonia
because the procedure cannot possibly irrigate the larynx.
A meta-analysis of 23 studies30 showed a fivefold prevalence of
oral candidiasis in patients taking inhaled corticosteroids with a
pMDI device and a threefold increase in those using DPIs,
although there is wide variation between studies both in
prevalence of clinical signs and symptoms and the correlation of
these with the ability to culture yeasts from throat swabs.31,32
A large questionnaire study of almost 900 patients suggested a
significant, threefold reduction of subjective oral symptoms by
mouth washing after using inhalers, but curiously this was
observed only in females using DPIs (and not pMDIs).33
Two studies34,35 showed that mouth washing after using
inhalers reduced the amount of residual drug remaining in the
oropharynx, but the possible clinical consequences of this
observation were not assessed. A further study suggested that
‘throat washing’ reduced colonisation of the oropharynx with
Candida species in patients inhaling fluticasone propionate
using a dry powder inhaler.36 Yokoyama et al.37 showed that
different types of mouth rinsing may be important, with rinsing
and gargling more effective than rinsing alone for removing
oropharyngeal fluticasone propionate deposited after using a DPI.
An additional potential benefit of mouth rinsing after inhaling
corticosteroids might be reduced deposition in the gut and thus
reduced systemic exposure. This is most likely to be relevant
for beclomethasone dipropionate, which has some oral
bioavailability, but unlikely to be relevant with other commonly
used inhaled corticosteroids, such as fluticasone propionate and
budesonide, as their oral bioavailability is so low. There do not
appear to be any specific studies on the effects of mouth rinsing
on systemic absorption of any inhaled corticosteroid.
Some studies suggest that dental caries are more frequent in
asthmatic than in non-asthmatic children,38 and one study39
reported that caries were somewhat less common in asthmatic
children undertaking regular mouth rinsing, although this
difference did not achieve statistical significance. In this study,
the lactose content of the filler in some of the DPI devices did
not emerge as a particular risk factor for caries. In another
case–control study of asthmatic patients aged 10–45 years
using DPI-delivered inhaled corticosteroids, there was no
significant difference in the incidence of dental caries in the
asthmatics compared with matched controls, although there was
some correlation within the asthmatic group between the
incidence of caries and the frequency of DPI use. Whether this
reflects possible effects of the drug or the filler, or both, is
unknown.40
Aside from this tentative, largely indirect evidence, there is no
clear evidence that dental caries are caused by inhaled anti-
asthma drugs. It has been hypothesised that dental caries may be
an unwanted effect of inhaled beta-2-agonist drugs reducing oral
pH.41 If this were the case, then clinical studies of the effects of
mouth rinsing on the incidence of caries might be confounded by
the fact that, in general, patients are advised to mouth-rinse after
inhaling corticosteroids but not ‘relievers’.
In summary, therefore, as far as we are aware the evidence for
any recommendation for regular mouth rinsing following the use
of inhaled corticosteroids is entirely empirical.42 One might
speculate that, with the increasing use of pMDI devices with
HFA propellants, which deliver drugs in true solution, and the
increased use of pro-drugs such as ciclesonide43 and beclometha-
sone dipropionate,44 which are metabolised to be active in the
lower respiratory tract rather than the mouth, this problem, if it
exists, may become less prevalent.
Conclusions
(1) Although it reduces residual deposition of inhaled anti-asthma
drugs, in the oropharynx, there is no clear evidence that
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mouth rinsing reduces oral thrush or dental caries or
influences the systemic bioavailability of the drugs.
(2) There are some data to suggest that children should be
advised to mouth-rinse after inhaling β2-agonists to reduce
dental caries, but this requires confirmation.
(3) Future studies should investigate how β2-agonists and
corticosteroids inhaled from pMDIs and DPIs affect the oral
microbiome and whether or not mouth rinsing has clinical
benefits in preventing thrush and caries in children and adults.
5. Moisture and dry powder inhalers (DPIs)
The release of respirable drug particles from DPIs requires
considerable force and at a relatively high flow rate to disperse
the powder and/or de-aggregate the particles to a respirable size
(o5 microns).45 This effort is required to overcome inter-
particular forces including Van der Waals forces and electrostatic
charge, more manifest with smaller particles.46
All powder formulations are sensitive to humidity, and dispersion
of fine particles is particularly impaired by moisture. In vitro studies
have demonstrated reduction in the fine-particle fraction of dry
powder aerosols with increasing relative humidity46–48 and that some
products are more susceptible to ambient humidity than others.49,50
There is some evidence that devices employing a reservoir to store
the dry powder are more susceptible to humidity than those in
which the powder is stored in individual sealed blisters or
capsules,47,51 although even the latter are somewhat sensitive to
moisture. In addition to ambient moisture, drugs delivered by DPI
devices are also vulnerable to wetting by inappropriate breathing
into the device, which causes condensation52 and a reduction in the
available inhaled fine-particle fraction of the drug.48
Remarkably, despite this relative wealth of data, we are aware of
no studies whatsoever reporting the effects of ambient humidity
on any clinical outcome of DPI therapy. Nevertheless, it would
seem sensible to instruct patients to store DPI devices in a dry
environment away from obvious sources of moisture, and not to
exhale or blow into them at any time.
Conclusions
(1) Dry powder devices should be stored in a dry environment, as
humidity reduces the dispersal properties of DPIs.
(2) Patients should be instructed not to exhale or blow into their
inhaler device, as this causes condensation and humidity.
(3) Future studies should investigate whether ambient humidity
has clinical consequences in patients using β2-agonists and
corticosteroids inhaled from different DPIs.
6. Patients can determine when their pMDI is empty
Clinical risk for patients who continue to use an empty inhaler is
obvious. There is a self-evident need for manufacturers and
prescribers to ensure that patients know how to keep track of the
dosages remaining in their inhalers.
While some pMDIs are provided with a dosage counter, many
are not. Without one it is very difficult to determine when the
device is empty. Some patients are instructed to keep track53,54 of
the dosages they use, but this can be cumbersome and unreliable,
and many patients are in any case not aware of the specified
maximum number of actuations listed by the manufacturer.55,56
In practice, a significant number of patients discover that their
inhalers are empty too late to avoid emergency hospital
attendance.55 Further, the absence of a counter may conversely
result in inappropriate early renewal of prescriptions and wastage.
In one study, more than 50% of 500 patients interviewed stated
that they refilled their prescriptions earlier than recommended by
national guidelines.55
This problem has long been recognised. ‘Floating’ of pMDIs in
water has been recommended53,56–58 as a means of determining
how full the device is, but this practice is inaccurate,59 may be
product specific54,59 and in over 25% of cases in one study60 it
resulted in water entering the device and obstructing the valves.
Consequently, this approach is clearly inadmissable. Currently,
therefore, there are no reliable means by which patients can
monitor the number of dosages remaining in their pMDIs unless
the device has a dosage counter.
Conclusions
(1) Patients cannot reliably determine the remaining dosages in a
pMDI without a counter.
(2) Prescribers should favour a device with a dose counter.
(3) If prescribing a device without a counter, ensure that the
patient is aware of the need to keep track of remaining
medication. A practical but work-intensive solution is to keep
count of the dosages used, and to advise the patient to
maintain a spare device available at all times.
(4) Future studies are needed to examine means to determine
when a pMDI without a counter is empty.
7. The use of a single design of inhaler to deliver different inhaled
drugs improves clinical outcomes
As pMDI and DPI devices require very different techniques for
optimal performance, it is reasonable to hypothesise that handling
errors and suboptimal drug delivery will be multiplied when a
patient has to use a range of different devices. This has been verified
in several studies showing that simultaneous use of different types
of inhaler device, particularly a mixture of pMDI and DPI devices, is
clearly predictive of increased errors in inhalation.61,62
Asking patients to mix inhaler devices may also adversely affect
their compliance with therapy. In a retrospective observational
study of over 11,000 COPD patients, multiple-inhaler users were
less likely to adhere and significantly more likely to discontinue
therapy altogether than single-inhaler users.63
In contrast, some studies suggest that mixing inhalation strategies
can improve clinical outcomes. For example, a study on 126 patients
with COPD treated with salbutamol and ipratropium64 found that
health-related quality of life and symptom scores improved
significantly more when using a combination of nebuliser therapy
morning and night along with a pMDI device in the afternoon and
evening rather than using either of these devices alone four times
daily. The relative advantages and disadvantages of using similar or
dissimilar inhaler devices to deliver both preventer and reliever
therapy remains a subject of lively debate.65,66
Although it would seem logical, wherever possible, to prescribe
drugs in identical devices or, if this is not possible, to confine
therapy to either pMDI or DPI devices rather than a mixture of the
two, evidence is lacking at least in terms of long-term clinical
outcomes in populations.
Conclusions
(1) Although there is evidence that asking patients to use inhalers
of a single type reduces errors and may improve compliance,
there is a paucity of evidence showing corresponding
favourable clinical outcomes.
(2) In the light of currently available evidence, it would seem
reasonable to restrict regular (preventer) inhaled medication
to a single type of device ( pMDIs or DPIs) whenever possible.
(3) Nevertheless, future studies are warranted to examine
whether using particular combinations of therapeutic
strategies in specific situations when treating patients with
asthma and COPD may be clinically beneficial.
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8. Patients who use an inhaler device they prefer have better
outcomes
The choice of devices when prescribing inhaled medication for
patients with asthma and COPD is influenced by many factors
including the patient’s preference and ability to use the device,
the availability of the drug in the preferred device and sometimes
the cost of the therapy and potential for reimbursement.67 An
observational study68 investigating the relationship between
patients’ satisfaction with their inhaler devices, their compliance
with therapy and the influence of these factors on health and self-
reported outcomes tentatively concluded that patient satisfaction
with inhaler devices influenced the attainment of asthma
treatment goals,69 largely through improving compliance. It is
difficult to assess in practice precisely what influences prescribing
of particular inhaler devices. For example, although it is well
known that subsets of patients find pMDIs difficult to use
correctly1,70–72 they are still widely prescribed; whether this
reflects patient or health-care professional preference is not clear.
When helping patients choose inhalation devices, they prefer
some objective input may be obtained by using appropriate
questionnaires such as the satisfaction with asthma treatment
questionnaire and others.73–75 These tools may also be used to
highlight patients who particularly dislike their existing device,
suggesting the need for a change. Although patient preference
may be ideal in deciding which device to prescribe, prescribers
should ensure that patients are able to use the prescribed device
correctly.76
Conclusions
(1) There is limited evidence supporting the hypothesis that
asthmatic patients’ satisfaction with their inhaler device is
associated with improved disease control.
(2) This satisfaction, or otherwise, should be assessed along with
other techniques, at asthma reviews, and the device should be
changed if appropriate.
(3) Future studies should investigate, for example, using
established questionnaires, whether patients who are satisfied
with their devices have better outcomes.
9. Dysphonia is caused by particular inhaler devices and changing
the device may relieve it
Dysphonia is a recognised unwanted local adverse effect of
inhaled corticosteroid therapy. In response to a patient’s
complaint of dysphonia, the attending health professional will
often be tempted to consider changing the inhalation device.
There is in fact little clinical evidence to justify or guide such a
strategy. A recent review43 concluded that dysphonia may be
improved by changing the inhaler device, or by reducing the
amount and/or frequency of inhaled corticosteroid therapy, or
changing the inhaled corticosteroid to ciclesonide (a small
particle, true solution pro-drug not active in the upper airways).
To address these issues adequately, studies are required in
which the same corticosteroid at the same dosage is administered
to patients with various devices, preferably in a crossover design,
but to our knowledge such studies have not been published. One
study investigated whether ad hoc changing of the device used to
deliver inhaled corticosteroid therapy has any demonstrable effect
on the voice.77 Patients reporting dysphonia while taking an
inhaled corticosteroid with a pMDI device alone were randomised
either to continue with a pMDI device with a Nebuhaler spacer or
to switch to an identical dosage of corticosteroid delivered using
a Turbohaler. Twelve weeks after switching, there were no
detectable differences in voice laboratory data, laryngoscopic
evidence of disordered glottic closure and symptom diary data
between the two groups. Gross laryngoscopic appearances of the
vocal cords were normal in almost half of the patients in the study.
Vocal cord bowing was rarely observed. Glottic closure was
detectably altered in 9 patients during the study period, but this
did not correlate with reported problems of vocalisation. Four
weeks after switching, 40% of the patients using the Turbohaler
and 8% of those using the pMDI and Nebuhaler scored their voice
status as significantly improved (Po0.02 for a between group
difference), but there was no significant difference between the
groups at 12 weeks (Turbohaler 52% improvement, Nebuhaler
23% improvement, P= 0.08 for between-group difference).
Conclusions
(1) Dysphonia is a recognised side effect of inhaled corticosteroid
therapy, but its relationship to the use of particular inhaler
devices, if any, is unclear.
(2) There is a paucity of published evidence that changing
inhalation devices used to deliver topical corticosteroids can
relieve dysphonia.
(3) Future studies are warranted to examine new strategies to
alleviate complaints of dysphonia, and to clarify the ability of
corticosteroid pro-drugs such as ciclesonide to reduce its
incidence.
10. Regular and proper use of inhaler devices improves asthma
outcomes
There is evidence in the literature1,78,79 linking incorrect inhaler
technique with poor treatment outcomes in asthma and COPD
such as treatment failure, unnecessary escalation of therapy and
increased exacerbations with unplanned use of medical services
and hospitalisation. These studies justify the statement, often
emphasised in guidelines, that if patients use their inhalers
correctly their asthma is likely to be better controlled.80–83
Separately, a number of carefully performed observational
studies84–86 have demonstrated that patients who follow their
prescribed treatment plan and adhere closely to prescribed
therapeutic regimens show a number of favourable outcomes
including fewer symptoms and exacerbations, and reduced use of
rescue medication; and randomised controlled trials
have shown reduced loss of lung function and mortality in patients
with COPD,87 and improved lung function and quality of life in
people with asthma.88 Conversely, poor adherence is associated
with increased morbidity and poorer clinical outcomes.89,90
It is tempting to assume that poor adherence to therapy and
poor inhaler technique go hand in hand in individual patients, but
so far there are no studies that clearly demonstrate this.
Consequently, it seems wise to address both issues separately
during reviews of asthma management. Although they do not
necessarily go hand in hand, careful instruction on inhaler
technique may confer the additional benefit of improving
adherence to therapy where it is lacking, and better outcomes.91
Conclusions
(1) Both incorrect inhaler technique and irregular usage of inhaler
medication are common causes of poor asthma control.
(2) Both must be diligently and regularly reviewed.
(3) Future studies should investigate whether poor inhaler
technique and poor adherence coexist in the same patients,
and how they interact to influence treatment outcomes.
AFTERWORD
We have presented this summary of the literature and our own
conclusions in order to stimulate debate about perfecting the
subtle and essential art of successful inhaler therapy. Although
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national and international asthma and COPD guidelines address
overarching issues such as the necessity to take inhaled
medications for obstructive airways disease, they tend not to
address the practical details. We felt it timely to take a critical view
of the commonly held beliefs that have become accepted truths
of inhaler ‘lore’ in the eyes of many health professionals.
Hopefully, we have raised sufficient doubt in the minds of
clinicians to stimulate further research on the practical aspects of
inhaler prescribing.
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